ArticleScientific reports2026
Folic acid-targeted albumin nanoliposomes co-loaded with paclitaxel and doxorubicin for enhanced treatment of lung cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cancer Drug Delivery with Nanoparticles and Biomolecules: Stimuli-Responsive, Theranostic, and AI-Guided Approaches.Materials (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lung cancer is a leading cause of cancer-related deaths globally. Co-delivery of chemotherapeutic agents with distinct properties via nanocarriers can enhance efficacy and reduce side effects. This study developed a novel targeted dual-drug delivery sustained-release nanomedicine to achieve precise therapy for lung cancer. Folic acid (FA)-targeted albumin nanoliposomes co-loaded with paclitaxel (PTX) and doxorubicin (DOX) (FA-ANLis-PTX-DOX) were prepared by reverse evaporation. The physicochemical properties were evaluated, and the drug loading efficiency and release profiles were tested. Hemolysis assays assessed the biological performance of the drug, while cell and animal studies evaluated the biosafety and antitumor activity of the nanomedicine. FA-ANLis-PTX-DOX had a size of 243.61 ± 5.84 nm, a zeta potential of 29.42 ± 4.77 mV, and high encapsulation efficiencies (PTX: 93.72 ± 4.13%; DOX: 94.24 ± 4.86%). The formulation showed sustained, pH-responsive drug release, with accelerated release under acidic conditions (pH 5.3). It exhibited low cytotoxicity against normal cells, high uptake in folate receptor-overexpressing lung cancer cells (A549, NCI-H1975), and minimal hemolysis (< 1%). In vivo, FA-ANLis-PTX-DOX significantly inhibited tumor growth and metastasis in A549 xenograft models, improved survival, and showed a favorable safety profile. The successfully developed FA-ANLis-PTX-DOX demonstrates favorable physicochemical properties, active targeting, pH-triggered release, and enhanced antitumor efficacy with good biocompatibility. This targeted co-delivery system presents a promising strategy for the precise treatment of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.